Cooperation Achieves Results at UNC-CH by Eubanks, Mary
Now that scientists have solved the code
for the human genome and are moving
forward to sequence the genomes of other
organisms, a significant challenge lies in
how to harness this vast amount of new
information to benefit society. Recog-
nizing that cross-communication and
cooperation among different research labs
is essential to realizing the potential of
genomic science for toxicology, the
NIEHS earmarked $37 million to establish
the Toxicogenomics Research Consortium
(TRC) in November 2001.
A major objective of the TRC is to link
investigator-initiated research projects at
five academic centers—the Massachusetts
Institute of Technology, Duke University,
the University of North Carolina at Chapel
Hill (UNC-CH), Oregon Health &
Science University, and the Fred Hut-
chinson Cancer Research Center/Univ-
ersity of Washington—in a collaborative
effort to understand how organisms
respond to chemical exposures and other
kinds of environmental stress. At UNC-
CH, investigator-initiated research projects
focus on different model systems—from
mice and cell lines to humans—all with a
common, unifying focus on environmental
challenges that cause DNA damage or
oxidative stress, leading to cancer. 
With the goal of finding molecular sig-
natures that can be used for early risk
assessment, these projects employ microar-
ray tools to assay for gene expression
responses to cancer-related chemicals.
Some use the same compounds that cancer
patients are already receiving, to gather
information on how different populations
may react to certain drugs.
Dampening the
Background Noise
In one TRC projects,
David W. Threadgill,
an assistant professor
of environmental
sciences and engi-
neering, uses mouse
models to investi-
gate differences in
response to various
tumor-inducing and
chemotherapeutic chem-
icals from one mouse strain
to another. In his model, all
the mice of one strain are essentially
identical, providing an unlimited number of
individuals that have the same genotype.
This experimental approach enriches the
opportunity to separate out what is “noise”
in the data from what is truly meaningful.
Threadgill’s lab is currently profiling about
a dozen mouse strains, some of which are
susceptible to certain types of cancer while
others are resistant. 
Among organisms, there is a wide
range of susceptibility to the effects of dif-
ferent toxicants. The classes of chemical
compounds that cause cancer—including
alkylating agents, DNA-damaging agents,
and toxicants that affect the cell cycle—
vary in the mechanisms by which they
cause the disease. There is also extensive
variation in the way different cancer
patients respond to treatment and how
they handle the toxic effects of different
chemical therapies. 
To better understand why this is so,
Threadgill exposes different mouse strains
to various chemicals over a variety of dose
regimens and time spans,
then compares the results
to a control group. Af-
ter exposure, tissue is
harvested from the
liver, colon, and
breast for extraction
of RNA that is con-
verted into cDNA.
The cDNA is hybrid-
ized to microarray
chips containing 17,000
mouse genes. If a gene
is turned on or up as a
result of exposure, it will fluo-
resce more brightly than the same
gene on the corresponding chip for the
control group. Analysis of the signals reveals
which genes increase their expression level
as a result of exposure to a particular toxi-
cant and which genes are turned down.
Threadgill explains, “Lots of genes are
turned on, up, or down. Comparison of
the signals from different strains reveals
which genes are unique to certain classes of
compounds, at what dose levels and time
treatments.” His lab also examines direct
causes of the associated physical changes
and their correlation with prior knowledge
of how certain classes of compounds affect
tissue. He has detected significant strain-
dependent differences in gene expression
in both baseline and treated colon tissue.
He says, “The characterization of these dif-
ferences in the context of disease and treat-
ment end points should reveal new insights
into the mechanistic causes of the cancer
end points.”
Screening thousands of genes and
expression changes presents a huge compu-
tational challenge to discern what the criti-
cal signatures are. Biostatisticians have
begun to mine the data collected by
Threadgill over the first two and a half
years of his project to evaluate thousands
of signals and identify similarities and dif-
ferences between treatment time courses,
exposure levels, and individual strains.
Knowing which genes are significant is
vital to finding prognostic markers for
whether an individual is susceptible to
effects from certain compounds and for
evaluating what makes certain individuals
more susceptible than others. 
Layers of Response
In a coordinated experimental design,
Charles M. Perou, an assistant professor of
genetics, is screening some of the same com-
pounds as Threadgill in his investigations of
the transcriptional response in breast cancer
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A perfect likeness. UNC-CH researcher David W. Threadgill uses strains of mice in which all
the animals have the identical genotype to study cancer susceptibility from exposure to a vari-
ety of environmental toxicants. Some of the mouse strains are resistant to cancer, while others
are more susceptible to the disease.
Cooperation Achieves Results at UNC-CHusing human cell lines from breast tumors
and immortalized breast epithelial cell lines
(that is, publicly available cell lines that
have been maintained over time for experi-
mental use). This may allow for compara-
tive analyses of results across different
model systems that could lead to new
insights into the resulting biological insults
from exposure to specific toxicants. Cell
lines are treated with different regimens,
and then examined for gene expression
changes using microarrays. 
Perou is also studying the effects of
these drugs on real breast tumors of
patients before, during, and after chemo-
therapy for comparison of similarities or
differences in experimental cell lines with
tumors in patients. In a paper in the June
2004 issue of Cancer Research, Perou’s lab
reported that a small but significant set of
genes were identified as being changed in
both in vitro cells and living tumors, and
that these are likely to be very important
in cellular response to toxicants. In this
study, 20–30 changes observed in the
expression profiles identified potential
candidate genes for a general response to
these compounds. 
Perou and colleagues have discovered
that although the compounds tested have
different mechanisms and targets in cells,
the overall cellular response to the different
drugs is the same—a sort of dominant
generic stress response that is similar across
genes. The secondary drug-specific
response pattern is layered on top of this
generic stress response pattern. Perou says,
“Arrays do a great job of implicating genes
in certain processes in response to different
drugs, but the genes involved in the
response are the same. . . . This leads to the
hypothesis that some people with reduced
ability to respond might be more suscepti-
ble because of variants in these generic
stress response genes.” 
Perou’s work has also uncovered unique
molecular signatures that distinguish two
subtypes of breast cancer. Patients with one
type will do well under the standard drug
therapies and survive. However, for those
with the other type, prognosis for survival if
given standard treatment is not good; more
aggressive treatment such as radical mastec-
tomy and radiation would be needed, and
even then the chances of survival are not
nearly as good. This complex overlapping
pattern of drug-specific response genes
embedded within the common response
will be reported in a second paper submit-
ted for publication.
Perou is particularly interested in the
generic stress phenomenon because indi-
viduals who have susceptible variants of
these genes could be unable to respond to
many different toxicants in their environ-
ment. He says, “Microarrays provide a big
list of candidate genes. The challenge is to
figure out [which genes] are the passen-
gers and [which] are the drivers, then
apply that information to population
studies to identify genetic variants that are
hyperactive and correspond to susceptibil-
ity.” Through the TRC, he says, it may
ultimately be possible to link findings and
design experiments such that scientists
can identify a common set of genes in
mice and humans for independent valida-
tion for susceptibility. “As we learn more
about evolutionarily conserved genes
across species that are involved in reac-
tions to environmental chemicals,” Perou
says, “we will have more confidence in the
scientific findings.”
Confidence Building
William K. Kaufmann, director of the
UNC-CH Program in Toxicogenomics
and director of the Genetic Susceptibility
Research Core in the UNC Center for
Environmental Health and Susceptibility,
studies expression of tumor suppressor
genes in the cell cycle. Kaufmann is inter-
ested in how changes in the DNA at the
ends of chromosomes provide life span
checkpoint monitors that signal the time
for aging cells to die. Experimental evi-
dence indicates that responses similar to
those involved in cell senescence occur in
breast, liver, and colon cells exposed to car-
cinogenic compounds. Such changes are
accompanied by reproducible gene expres-
sion patterns. 
Kaufmann says, “When the same unex-
pected patterns of response are seen in lines
from several different individuals, our con-
fidence that the response to stress is biologi-
cally meaningful increases.” Knowledge
gained from the characterization of modu-
lations in expression of genes as a result of
exposure to different carcinogens could one
day provide a fingerprint to enable design
of precise treatment strategies for specific
individuals exposed to different toxicants.
As the robustness of microarray tech-
nology for gene expression profiling
improves and becomes more standardized,
scientists will be able to employ molecular
signatures to tailor therapies as well as con-
duct exposure risk assessment. Kaufmann
concludes that in spite of sometimes feeling
overwhelmed by too many genes and the
need for a bigger computer, the UNC-CH
microarray research projects are producing
a data-rich picture, and are spawning whole
new areas of discipline to look for patterns
of change. Such individual scientific discov-
eries and applications of the principles of
toxicogenomics are resulting in a serendipi-
tous research crossover that will continue to
spur insights, leading to faster, broader, and
more effective applications for public
health. –Mary Eubanks
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Molecular mysteries. UNC-CH researchers are elucidating how susceptibility to breast cancer
is impacted by a “generic” stress response that is similar across genes. Such a generic
response underlies characteristic drug-related responses, which molecular signatures indicate
vary from person to person.